IP Library › Granted Patent US 12,383,524
Granted Patent B2
US 12,383,524 · App. 17/461,857 · Granted Aug 12, 2025

Therapeutic compositions of undecylenic acid and arginine

Inventors: Thomas F. Rau (Heidelberg Heights, AU); Geoffrey W. Rogers (Fitzroy, AU)
Assignee: Wintermute Biomedical, Inc.
A61K31/20A01N33/12A01N37/06A01N37/44A61K9/0014A61K31/198A61K31/201A61K47/55A61P31/02A61P31/04A61K31/14A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,524
App. No.
17/461,857
Granted
Aug 12, 2025
Kind
B2
Abstract

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine.

Claims (22)

1. A therapeutic composition comprising a complex of fatty acid: amino acid in a molar ratio of between 1:0.6 to 1:1.6 in an aqueous solution that is enriched so that at least 30% of the complex of fatty acid: amino acid has a lamellar supramolecular structure within the aqueous solution, wherein the fatty acid is undecylenic acid and the amino acid is L-arginine, and wherein the composition excludes rhein.

2. The therapeutic composition of claim 1 , wherein the lamellar supramolecular structure comprises 3 or more layers.

3. The therapeutic composition of claim 1 , wherein the therapeutic composition is substantially free of alcohol.

4. The therapeutic composition of claim 1 , further comprising an excipient, diluent, or carrier or fragrance.

5. The therapeutic composition of claim 1 , wherein the lamellar supramolecular structure has a diameter of between 10 and 100 nm.

6. The therapeutic composition of claim 1 , wherein the therapeutic composition is formulated as a liquid or emulsion suitable for topical administration to a human.

7. The therapeutic composition of claim 1 , further comprising at least 0.1 g/L of monoterpene/monoterpenoid.

8. The therapeutic composition of claim 7 , wherein the monoterpene/monoterpenoid comprises thymol.

9. The therapeutic composition of claim 1 , further comprising at least 5.0 g/L of monoterpene/monoterpenoid.

10. The therapeutic composition of claim 1 , wherein a pH of the therapeutic composition is between 6 and 10.

11. The therapeutic composition of claim 1 , further comprising an odor modifier.

12. The therapeutic composition of claim 1 , further comprising a fragrance oil odor modifier.

13. The therapeutic composition of claim 1 , further comprising an odor modifier between about 0.05% (w/w) and 10% (w/w).

14. The therapeutic composition of claim 1 , further comprising a vanillin odor modifier.

15. The therapeutic composition of claim 1 , further comprising a eucalyptus , lemon blossom, black pepper and/or lavender odor modifier.

16. A therapeutic composition comprising a complex of fatty acid: amino acid in a molar ratio of between 1:0.6 to 1:1.6 in an aqueous solution that is enriched so that at least 30% of the complex of fatty acid: amino acid is part of a lamellar supramolecular structure within the aqueous solution, wherein the fatty acid is undecylenic acid and the amino acid is L-arginine, and wherein the composition excludes rhein.

17. A method of treating a patent to destroy a virus, the method comprising topically applying a therapeutic composition comprising a complex of fatty acid: amino acid in a molar ratio of between about 1:0.6 to about 1:1.6 in an aqueous solution that is enriched so that at least 30% of the complex of fatty acid: amino acid has a lamellar supramolecular structure within the aqueous solution, wherein the fatty acid is undecylenic acid and the amino acid is L-arginine.

18. The method of claim 17 , wherein the virus is a herpes virus.

19. The method of claim 17 , wherein the virus is a varicella zoster virus.

20. A method of treating a surface to destroy a virus, the method comprising topically applying a therapeutic composition to the surface, wherein the therapeutic composition comprises a complex of fatty acid: amino acid in a molar ratio of between about 1:0.6 to about 1:1.6 in an aqueous solution that is enriched so that at least 30% of the complex of fatty acid: amino acid has a lamellar supramolecular structure within the aqueous solution, wherein the fatty acid is undecylenic acid and the amino acid is L-arginine.

21. The method of claim 20 , wherein the virus is a herpes virus.

22. The method of claim 20 , wherein the virus is a varicella zoster virus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2021
From: RAU, THOMAS F.; ROGERS, GEOFFREY W.
To: WINTERMUTE BIOMEDICAL, INC.
Reel/Frame 057589/0513 →
Continuity (6)
Continuation 16836881 · Mar 31, 2020
Continuation In Part PCTUS2019054044 · Oct 1, 2019
Provisional Application 62845858 · May 9, 2019
Provisional Application 62845859 · May 9, 2019
Provisional Application 62739844 · Oct 1, 2018
Related Publication 20210386700A1 · Dec 16, 2021
References Cited (93)
US 4147769A · Dea et al. · 1979 [cited by applicant]
US 4150052A · Watson et al. · 1979 [cited by applicant]
US 5260066A · Wood et al. · 1993 [cited by applicant]
US 5766614A · Yong · 1998 [cited by applicant]
US 6015798A · Ogilvie et al. · 2000 [cited by applicant]
US 6696081B2 · Grinstaff et al. · 2004 [cited by applicant]
US 6841174B2 · Shalaby et al. · 2005 [cited by applicant]
US 7288265B1 · Rolf · 2007 [cited by applicant]
US 7671011B2 · Shai et al. · 2010 [cited by applicant]
US 10195242B2 · Hale et al. · 2019 [cited by applicant]
US 10894788B2 · Kanouni et al. · 2021 [cited by applicant]
US 11065220B2 · Weston et al. · 2021 [cited by applicant]
US 11103475B2 · Rau et al. · 2021 [cited by applicant]
US 11154524B2 · Rau et al. · 2021 [cited by applicant]
US 20060159746A1 · Troup et al. · 2006 [cited by applicant]
US 20070258913A1 · Rossel · 2007 [cited by applicant]
US 20080026974A1 · Barnhart et al. · 2008 [cited by applicant]
US 20080206159A1 · Tamarkin et al. · 2008 [cited by applicant]
US 20080253973A1 · Tamarkin et al. · 2008 [cited by applicant]
US 20090068128A1 · Waddington · 2009 [cited by applicant]
US 20100111879A1 · Tamarkin et al. · 2010 [cited by applicant]
US 20110034557A1 · Jarrell et al. · 2011 [cited by applicant]
US 20120328544A1 · Stockel et al. · 2012 [cited by applicant]
US 20160066578A1 · Ala'Aldeen et al. · 2016 [cited by applicant]
US 20220040135A1 · Rau et al. · 2022 [cited by applicant]
CN 1969984A · 2007 [cited by applicant]
CN 101991726A · 2011 [cited by applicant]
CN 102178842A · 2011 [cited by applicant]
EP 1842437A1 · 2007 [cited by applicant]
EP 1595936B1 · 2011 [cited by applicant]
GB 2051574A · 1981 [cited by applicant]
JP 11269034A · 1999 [cited by applicant]
JP H11513561A · 1999 [cited by applicant]
JP 2000281528A · 2000 [cited by applicant]
JP 2002114670A · 2002 [cited by applicant]
JP 2008208059A · 2008 [cited by applicant]
JP 2009263231A · 2009 [cited by applicant]
JP 2013520398A · 2013 [cited by applicant]
RU 2356247C2 · 2009 [cited by applicant]
WO WO00029025A1 · 2000 [cited by applicant]
WO WO2004026840A1 · 2004 [cited by applicant]
WO WO2004110341A2 · 2004 [cited by applicant]
WO WO2005049553A1 · 2005 [cited by applicant]
WO WO2005123101A1 · 2005 [cited by applicant]
WO WO2006046025A1 · 2006 [cited by applicant]
WO WO2008111532A1 · 2008 [cited by applicant]
WO WO2009090648A2 · 2009 [cited by applicant]
WO WO2012090205A2 · 2012 [cited by applicant]
WO WO2018148763A1 · 2018 [cited by applicant]
Jones et al.; Wound Dressings; BMJ; 332(7544); pp. 777-780; Mar. 30, 2006. [cited by applicant]
Kharkevich; Pharmacology: Textbook; 10th edition; pp. 73; 2010 (the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publicati… [cited by applicant]
Kholodov et al.; Clinical pharmacokinetics, Medicine; pp. 83-98, 134-138m 160m 378-380; 1985 (the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the… [cited by applicant]
Sergeeva; A short course in molecular pharmacology; pp. 10; 1975 (the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publica… [cited by applicant]
Angele et al.; L-arginine: a unique amino acid for improving depressed wound immune function following hemorrhage; European Surgical Research; 34(1-2); pp. 53-60; Jan.-Apr. 2002. [cited by applicant]
Atilano et al.; Wall teichoic acids of [cited by applicant]
Bourne et al.; Effect of Undecylenic Acid as a Topical Microbicide Against Genital Herpes Infection in Mince and Guinea Pigs; Antiviral Research; 40(3); pp. 139-144; Jan. 1, 1999. [cited by applicant]
Brown et al.; Methicillin resistance in [cited by applicant]
Brown et al.; [cited by applicant]
Chung et al.; Rhein affects arylamine N-acetyltransferase activity in Helicobacter pylori from peptic ulcer patients; Journal of Applied Toxicology; 18(2); pp. 117-123; Mar. 1, 1998. [cited by applicant]
Ding et al.;Screening for Novel Quorum-Sensing Inhibitors to Interfere with the Formation of Pseudomonas aeruginosa Biofilm; Journal of Medical Microbiology; 60(12); pp. 1827-1834; Dec. 1, 2011. [cited by applicant]
Diep et al.; Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant [cited by applicant]
Diep et al.; The arginine catabolic mobile element and staphylococcal chromosomal cassette rnec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant [cited by applicant]
drugs.com; Rhubarb; 8 pages; retrieved from the internet (https://www.drugs.com/npp/rhubarb.html) on May 8, 2018. [cited by applicant]
Garcia-Sosa et al.; Chrysophanol, an antimicrobial anthraquinone from the root extract of colubrina greggii; Journal of the Mexican Chemical Society; 50(2); pp. 76-78; Jun. 2006. [cited by applicant]
Green et al.; Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens; Immunology Letter; 43(1-2); pp. 87-94; Dec. 1, 1994. [cited by applicant]
Handa et al.; (Ed); Extraction technologies for medicinal and aromatic plants; United Nations Industrial Development Organization and the International Centre for Science and High Technology, Trieste; 266 pages; (year o… [cited by applicant]
Hatano et al.; Phenolic Constituents of Cassia Seeds and Antibacterial Effect of Some Naphthalenes and Anthraquinones on Methicillin-Resistant [cited by applicant]
Helms et al.; Natural Treatment of Chronic Rhinosinusitis; Alternative Medicine Reviews; 11(3); pp. 196-207; Sep. 1, 2006. [cited by applicant]
Lai et al.; Rhein induced apoptosis through the endoplasmic reticulum stress, caspase- and mitochondria-dependent pathways in SCC-4 human tongue squamous cancer cells; In Vivo; 23(2); pp. 309-316; Mar. 1, 2009. [cited by applicant]
Lee et al.; Synergistic effect of emodin in combination with ampicillin or oxacillin against methicillin-resistant [cited by applicant]
Li et al.; Potent In Vitro Antifungal Activities of Naturally-Occurring Acetylenic Acids; Antimicrobial Agents and Chemotherapy; 52(7); pp. 2442-2448; Jul. 1, 2008. [cited by applicant]
Macmicking et al.; Identification of nitric oxide synthase as a protective locus against tuberculosis; Proceedings of the National Academy of Sciences; 94(10); pp. 5243-5248; May 13, 1997. [cited by applicant]
Macmicking et al.; Nitric oxide and macrophage function; Annual Review of Immunology; 15(1); pp. 323-350; Apr. 15, 1997. [cited by applicant]
Mclain et al.; Undecylenic Acid Inhibits Morphogenesis of Candida albicans; Antimicrobial Agents and Chemotherapy; 44(10); pp. 2873-2875; Oct. 1, 2000. [cited by applicant]
Mohamed et al.; Antibacterial activity of novel cationic peptides against clinical isolates of multi-drug resistant [cited by applicant]
Monograph; Undecylenic Acid; , Alternative Medicine Review; 7(1); pp. 68-70; Feb. 2002. [cited by applicant]
Morris; Enzymes of arginine metabolism; The Journal of Nutrition; 134 (10); pp. 2743S-2747S; Oct. 1, 2004. [cited by applicant]
Nakaki et al.; L-arginine-induced hypotension; The Lancet; 336(8716); pp. 696; Sep. 15, 1990. [cited by applicant]
Nelson; Undecylenic acid in the treatment of psoriasis and neurodermatitis; California Medicine; 74(1); pp. 17; Jan. 1951. [cited by applicant]
Rattner et al.; Treatment of psoriasis with undecylenic acid by mouth; Journal of the American Medical Association; 146(12); pp. 1113-1115; Jul. 21, 1951. [cited by applicant]
Seguin et al.; Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells; Journal of Experimental … [cited by applicant]
Shafran et al.; Topical undecylenic acid for herpes simplex labialis: a multicenter, placebo-controlled trial; Journal of Infectious Diseases; 176(1); pp. 78-83; Jul. 1, 1997. [cited by applicant]
Testa et al.; Hydrolysis in drug and prodrug metabolism: Chemistry, Biochemistry, and Enzymology; Wiley-VCH, Zurich, Switzerland, 2003; 11 pages; retrieved from the interent (http://sutlib2.sut.ac.th/sut_contents/H89132… [cited by applicant]
Thurlow et al.; Functional Modularity of the Arginine Catabolic Mobil Element Contributes to the Success of USA300 Methicillin-Resistant [cited by applicant]
Kosikowska et al.; Antimicrobial Activity and Total Content of Polyphenols or [cited by applicant]
Wrong; Undecylenic acid administered orally in the treatment of psoriasis; Can. Med. Assoc. J..; 63(6); pp. 543-545; Dec. 1950. [cited by applicant]
Wu et al.; Antimicrobial properties and toxicity of anthraquinones by microcalorimetric bioassay; Chinese Journal of Chemistry; 24(1); pp. 45-50; Jan. 1, 2006. [cited by applicant]
Yu et al.; Global transcriptional response of [cited by applicant]
Zhang et al.; Lamellar supramolecular materials based on a chelated metal complex for organic dye adsorption; RSC advances; 6(40); pp. 33295-33301; Mar. 29, 2016. [cited by applicant]
Rau et al.; U.S. Appl. No. 17/282,185 entitled “Therapeutic compositions,” filed Apr. 1, 2021. [cited by applicant]
Kotan et al.; Screening of antibacterial activities of twenty-one oxygenated monoterpenes; Zeitschrift für Naturforschung C; Journal of Biosciences, 62(7-8); pp. 507-513; Aug. 1, 2007. [cited by applicant]
Marchese et al.; Antibacterial and antifungal activities of thymol: A brief review of the literature. Food chemistry; vol. 210; pp. 402-414; Nov. 1, 2016. [cited by applicant]
Nall et al.; Dietary supplementation of L-arginine and conjugated linoleic acid reduces retroperitoneal fat mass and increases lean body mass in rats; The Journal of nutrition; 139(7); pp. 1279-1285; Jul. 1, 2009. [cited by applicant]